Agp Limited · PSX:AGP
Agp — Investor Presentation (November 2025)
23 slides from Agp's investor presentation, Nov 25, 2025
Slide 1: Corporate Briefing Session 2025
CORPORATE BRIEFING SESSION 2025 November 25, 2025
Slide 2: AGP Management Representatives
AGP MANAGEMENT REPRESENTATIVES Muhammad Kamran Nasir Group Chief Executive Officer Muhammad Kamran Mirza Chief Executive Officer OBS AGP & OBS PAK Junaid Aslam Chief Financial Officer 2
Slide 3: Table of Contents
TABLE OF CONTENTS Corporate Profile Key Achievements & Developments Financial Performance Future Outlook Questions and Answers 3
Slide 4: Corporate Profile
CORPORATE PROFILE 4
Slide 5: Corporate Information
CORPORATE PROFILE CORPORATE INFORMATION Pattern of Shareholding Shariah Compliance Meezan Bank Limited reviewed the AitkenStuart Pakistan accounts of AGP and found them to be 55.80% (Pvt.) Limited in compliance with Karachi Meezan Islamic Index – 30 Criteria set out by Muller & Phipps Pakistan Stock
Slide 6: Board of Directors
CORPORATE PROFILE BOARD OF DIRECTORS Tariq Moinuddin Khan Muhammad Kamran Nasir Zafar Iqbal Sobani Maleeha Bangash Chairman Chief Executive Officer Independent Director Independent Director Kamran Nishat Mahmud Yar Hiraj Muhammad Kamran Mirza Non-Executive Director Non-Executive Director Non-Executi
Slide 7: Our Journey
CORPORATE PROFILE OUR JOURNEY 1989 1991 1995 2003 2007 2013 Signs an Acquired 30% AGP (Pvt.) Ltd. Enters into a JV Purchase Eli Lilly Purchase UCB agreement with stake of Eli Lilly starts with Eli Lilly UCB Belgium to brand rights for brand rights for Pakistan commercial Pakistan for manufacture & C
Slide 8: Group Structure
CORPORATE PROFILE GROUP STRUCTURE West End 16 Pte. Ltd. (Singapore) 70% OBS Healthcare (Pvt.) Ltd. (Local Holdco) 100% Aitkenstuart Pakistan (Pvt.) Ltd. (Local Holdco) 100% 55.8% 80% Aspin Pharma (Pvt.) Ltd. 4.79% AGP Ltd. OBS Pharma (Pvt.) Ltd. (Former J&J Business) (Former Eli Lilly Business) (For
Slide 9: Corporate Information
CORPORATE PROFILE CORPORATE INFORMATION 3 Manufacturing Plants The Company has 3 state-of-the-art cGMP- certified plants. 2,939 Employees 128 Brands AGP Group employees include both AGP has 128 brands, comprising management and third-party over 270 SKUs. contract workers. 03 02 04 Incorporated in 19
Slide 10: Manufacturing Facilities
CORPORATE PROFILE MANUFACTURING FACILITIES AGP Plant 2 AGP Plant 1 AGP Plant 3 (Former Eli Lilly JV) General Medicines Facility Cephalosporins Facility Nutraceuticals Facility SITE, Karachi SITE, Karachi SITE II, Karachi GMP Certified; GMP Certified; ISO 9001, ISO 14001 and GMP Certified FDA Registe
Slide 11: Area of Focus: AGP & Subsidiaries
AREA OF FOCUS AGP & SUBSIDIARIES Therapeutic Class Presence Increasing Focus on Chronic Therapies Musculo- Blood + B.Forming Skeletal System Organs Top Acute Top Chronic 3% 2% Chronic • Azomax Other • Norvasc Nervous System 19% • Rigix 4% • Azomax • Cardura • Osnate-D 4% • Ceclor • Doxium • Ceclor •
Slide 12: Leading Brands of AGP & Subsidiaries
CORPORATE PROFILE LEADING BRANDS OF AGP & SUBSIDIARIES PKR 4.4+ bn PKR 3.9+ bn PKR 2.2+ bn PKR 2+ bn PKR 1.6+ bn PKR 0.9+ bn PKR 0.8+ bn PKR 0.7+ bn PKR 0.6+ bn AGP Group offers a wide range of 128 products and 270+ SKU Source: IQVIA MAT SEP 2025 12
Slide 13: Key Achievements & Developments
KEY ACHIEVEMENTS & DEVELOPMENTS 13
Slide 14: Climbing Up the Rank
CORPORATE PROFILE CLIMBING UP THE RANK Getz 72,598 Sami 65,500 Abbott 64,598 GSK 62,099 Martin Dow 46,910 Searle 46,257 Hilton 43,075 OBS 40,654 Ranked 8th High-Q 39,373 Haleon 36,059 Bosch 33,008 Highnoon 29,461 Hoechst 27,672 CCL 27,470 Atco 26,256 AGP Consolidated 26,013 Ranked 16th Source: IQVIA
Slide 15: Achievements for 2025
KEY ACHIEVEMENTS & DEVELOPMENTS ACHIEVEMENTS FOR 2025 BCSR Award AGP won the 1st position in ‘Pharmaceutical Category’ at the Best Corporate & Sustainability Awards 2024, jointly held by The Institute of Chartered Accountants of Pakistan (ICAP) and Institute of Cost and Management Accountants of Pak
Slide 16: Financial Performance
FINANCIAL PERFORMANCE 16
Slide 17: Highlights of Financial Statements – 9M 2025 (Consolidated)
FINANCIAL PERFORMANCE HIGHLIGHTS OF FINANCIAL STATEMENTS – 9M 2025 (CONSOLIDATED) Revenue Gross Profit Particulars Value Unit (YTD SEP 2025) Growth Growth 20,342mn 12,091mn Industry 15.43% -0.12% Increase: 15.3% ↑ Increase: 23.2% ↑ AGP 16.98% 3.90% *Source IQVIA EBITDA Net Profit 5,953mn 2,853mn GP
Slide 18: Financial Snapshot – AGP Consolidated
FINANCIAL PERFORMANCE FINANCIAL SNAPSHOT – AGP CONSOLIDATED (Figures in PKR mn) Dec-20 Dec-21 Dec-22 Dec-23 Dec-24 Sept-25 Sales 6,946 9,317 14,459 18,743 25,034 20,342 Cost of sales (3,086) (4,262) (7,128) (8,703) (10,482) (8,251) Gross profit 3,861 5,055 7,331 10,040 14,551 12,091 Administrative e
Slide 19: Strong Revenue Growth Despite Economic Challenges
FINANCIAL PERFORMANCE STRONG REVENUE GROWTH DESPITE ECONOMIC CHALLENGES 25,034 3,237 20,342 18,743 6,257 2,716 1,673 14,459 5,381 5,057 4,571 9,317 1,896 15,540 12,013 12,245 9,887 6,946 7,420 2020 2021 2022 2023 2024 9M 2025 AGP (PKR mn) OBS AGP (PKR mn) OBS PK (PKR mn) Recent Acquisitions have Pro
Slide 20: Future Outlook
FUTURE OUTLOOK 20
Slide 21: Future Outlook
FUTURE OUTLOOK AGP aims to post strong revenue and profitability growth in the coming years thereby generate value for shareholders 1 2 Launch of New Products 3 each year to diversify the Target more than market Increase focus on portfolio along with a focus volumetric growth to Institutional and OT
Slide 22: International Business Road Map
INTERNATIONAL BUSINESS ROAD MAP GLOBAL TERRITORIAL UPDATES Existing Markets New Markets to be commercialized by 2026-2027 Asia & Middle East Region Afghanistan Cambodia Sri Lanka Yemen Iraq Myanmar Azerbaijan Uzbekistan Tajikistan Central & South American Region El Salvador Guatemala Nicaragua Hondu
Slide 23: Questions & Answers
QUESTIONS & ANSWERS 23